Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroblastoma

Interventions

BIOLOGICAL: GM-CSF + Naxitamab

Sponsor

Y-mAbs Therapeutics